Cambrex Corp. (CBM) Tops Q2 EPS by 22c, Revenues Beat; Affirms FY18 Adj. Net Revenue & Adj. EBITDA Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cambrex Reports Second Quarter 2018 Financial Results
August 2, 2018 6:40 AM EDT- Net Revenue increased 13% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 -
- 2018 full year Adjusted Net Revenue Growth and Adjusted EBITDA guidance reaffirmed -
- Agreement to acquire Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base -
- Conference call at 8:30 a.m. ET on August 2, 2018 -
EAST RUTHERFORD, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients... More
